The drug, plus chemotherapy, shows a significant survival benefit.
Treatment will be first to target a specific type of advanced lung cancer.
The FDA has recently approved new dosage form and two new indications for the drug.
A new non-small cell lung cancer (NSCLC) treatment is available to healthcare providers immediately.
Here are the top 3 new approvals from FDA.